Adjunctive Vortioxetine in Schizophrenia

Trial Profile

Adjunctive Vortioxetine in Schizophrenia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms AVIS
  • Most Recent Events

    • 16 Feb 2016 Planned end date changed from 1 Sep 2018 to 1 Jan 2019, as reported by ClinicalTrials.gov.
    • 16 Feb 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2018, as reported by ClinicalTrials.gov.
    • 16 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top